Therapeutic drug monitoring of polymyxin B by LC–MS/MS in plasma and urine
- 19 June 2020
- journal article
- research article
- Published by Future Science Ltd in Bioanalysis
- Vol. 12 (12), 845-855
- https://doi.org/10.4155/bio-2020-0051
Abstract
Background: A robust and rapid method for therapeutic drug monitoring (TDM) is urgently needed for polymyxin B, which is a last-line antibiotic for multidrug-resistant gram-negative bacteria infection. Methodology: A 3-min run of LC–MS/MS method was established to determine the main components of polymyxin B (polymyxin B1 and B2) in human plasma or urine. Solid-phase extraction was employed to eliminate the matrix effect from complicated samples from patients. Results: The calibration range was 0.050–5.00 and 0.0110–0.549 μg/ml for polymyxin B1 and B2, respectively, in plasma and urine. The precision and accuracy of quality controls, matrix effect, extraction recovery and stability were all validated and satisfied with the ICH requirements. The method was successfully applied to a pharmacokinetic study in healthy subjects and TDM in patients. Conclusion: The rapid LC–MS/MS method was validated for polymyxin B in plasma and urine, and robust for TDM.Keywords
This publication has 26 references indexed in Scilit:
- Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection ModelAntimicrobial Agents and Chemotherapy, 2018
- Critical Need for Clarity in Polymyxin B DosingAntimicrobial Agents and Chemotherapy, 2017
- Comparative Pharmacokinetic Profiling of Different Polymyxin B ComponentsAntimicrobial Agents and Chemotherapy, 2016
- Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasmaJournal of Antimicrobial Chemotherapy, 2008
- Polymyxins RevisitedClinical Microbiology Reviews, 2008
- Optimizing Use of Colistin and Polymyxin B in the Critically IllSeminars in Respiratory and Critical Care Medicine, 2007
- Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infectionsThe Lancet Infectious Diseases, 2006
- Old Polymyxins Are Back: Is Resistance Close?Clinical Infectious Diseases, 2006
- Toxicity of polymyxins: a systematic review of the evidence from old and recent studiesCritical Care, 2006
- PmrA–PmrB‐regulated genes necessary for 4‐aminoarabinose lipid A modification and polymyxin resistanceMolecular Microbiology, 1998